PainReform (PRFX) Competitors $2.27 -0.05 (-2.16%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. PRPH, SLXN, BFRI, INDP, OMGA, MYNZ, AIM, GNPX, LIPO, and AYTUShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include ProPhase Labs (PRPH), Silexion Therapeutics (SLXN), Biofrontera (BFRI), Indaptus Therapeutics (INDP), Omega Therapeutics (OMGA), Mainz Biomed (MYNZ), AIM ImmunoTech (AIM), Genprex (GNPX), Lipella Pharmaceuticals (LIPO), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. PainReform vs. ProPhase Labs Silexion Therapeutics Biofrontera Indaptus Therapeutics Omega Therapeutics Mainz Biomed AIM ImmunoTech Genprex Lipella Pharmaceuticals Aytu BioPharma PainReform (NASDAQ:PRFX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends. Is PRFX or PRPH more profitable? PainReform has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A -450.64% -241.33% ProPhase Labs -217.64%-62.92%-30.22% Which has preferable earnings & valuation, PRFX or PRPH? PainReform has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$9.34M-$147.33-0.02ProPhase Labs$6.77M2.07-$16.78M-$1.26-0.27 Which has more volatility and risk, PRFX or PRPH? PainReform has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500. Does the MarketBeat Community prefer PRFX or PRPH? ProPhase Labs received 111 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformPainReformOutperform Votes375.00% Underperform Votes125.00% ProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% Do analysts rate PRFX or PRPH? PainReform currently has a consensus target price of $8.00, indicating a potential upside of 252.42%. Given PainReform's stronger consensus rating and higher possible upside, equities research analysts clearly believe PainReform is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to PRFX or PRPH? In the previous week, ProPhase Labs' average media sentiment score of 0.98 beat PainReform's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Overall Sentiment PainReform Neutral ProPhase Labs Positive Do institutionals and insiders hold more shares of PRFX or PRPH? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryPainReform beats ProPhase Labs on 9 of the 15 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99M$6.55B$5.37B$7.70BDividend YieldN/A3.20%5.44%4.32%P/E Ratio-0.026.9722.0918.22Price / SalesN/A266.04398.07105.44Price / CashN/A65.6738.2034.62Price / Book0.026.436.704.18Net Income-$9.34M$142.50M$3.20B$247.50M7 Day Performance10.73%7.39%5.27%5.92%1 Month Performance-11.67%-6.39%-4.75%-3.62%1 Year Performance-32.38%-0.84%17.44%4.75% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform2.083 of 5 stars$2.27-2.2%$8.00+252.4%-32.3%$1.99MN/A-0.024Gap DownPRPHProPhase Labs0.8935 of 5 stars$0.30-2.3%N/A-93.4%$7.20M$6.77M-0.24130SLXNSilexion TherapeuticsN/A$0.85+0.8%$5.00+486.8%N/A$7.17MN/A0.00N/ABFRIBiofrontera2.7957 of 5 stars$0.80-4.6%$7.00+773.9%-50.1%$7.11M$37.32M-0.3570Gap DownINDPIndaptus Therapeutics2.1291 of 5 stars$0.51+6.3%$8.50+1,566.7%-78.7%$6.93MN/A-0.306News CoverageNegative NewsOMGAOmega Therapeutics1.8202 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.6%$6.92M$8.10M-0.09120Gap UpMYNZMainz Biomed1.7041 of 5 stars$3.37+1.2%$14.00+315.4%-91.1%$6.74M$893,991.00-0.0530Gap DownAIMAIM ImmunoTech1.8874 of 5 stars$0.09-22.3%$2.75+2,908.8%-78.7%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeGNPXGenprex4.403 of 5 stars$0.26-0.8%$10.00+3,680.7%-87.9%$6.39MN/A0.0020News CoveragePositive NewsLIPOLipella Pharmaceuticals2.045 of 5 stars$2.45+0.4%N/A-54.8%$6.25M$536,357.00-0.584Gap DownAYTUAytu BioPharma1.099 of 5 stars$1.00-3.7%N/A-62.5%$6.17M$77.23M-0.69160Positive NewsGap Up Related Companies and Tools Related Companies PRPH Competitors SLXN Competitors BFRI Competitors INDP Competitors OMGA Competitors MYNZ Competitors AIM Competitors GNPX Competitors LIPO Competitors AYTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRFX Stock Free PRFX Stock Alerts